Study Comparing Automated Peritoneal Dialysis with Remote Management and Continuous Ambulatory Peritoneal Dialysis on Outcomes and Quality of Life in End-Stage Renal Disease Patients

What this Trial Is About

Researchers are comparing two types of peritoneal dialysis treatmentsautomated peritoneal dialysis with remote patient management APD-RPM and continuous ambulatory peritoneal dialysis CAPDin patients with end-stage renal disease. This observational, multicenter study plans to enroll 750 adult patients aged 18 to 75 years who have been on peritoneal dialysis for at least three months and who have a rapid peritoneal solute transfer rate. The study aims to assess the effects of these treatments on patients prognosis and quality of life over a period of 156 weeks. Participants will be divided into two groups, with about 250 receiving APD-RPM and 500 receiving CAPD. APD-RPM involves a recommended mode of continuous circulating peritoneal dialysis with a dialysis dose ranging from 5 to 10 liters per day and glucose concentrations starting from a low level. Remote monitoring tracks treatment details and alerts. The CAPD group receives a dialysis dose of 5 to 10 liters per day during the run-in period, with exchanges occurring 2 to 5 times during the day and once at night. Glucose concentrations in CAPD vary from 1.5% to 4.25%, and treatments can be adjusted based on individual patient factors. Patients will attend follow-up visits approximately every 12 weeks for up to 156 weeks. Researchers will monitor outcomes including all-cause deaths, technical failure, quality of life, return to society, cardio-cerebrovascular events, ultrafiltration rate, hypertension, peritonitis, nutritional status, dialysis adequacy, hospitalizations, and treatment adjustments. The study collects detailed clinical and laboratory data to understand long-term effects and safety of the two dialysis methods.

Comparative Study of Prognosis and QOL Between APD-RPM and CAPD